Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial

BACKGROUND: Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has neuroprotective effects in preclinical models of Parkinson’s disease. We investigated whether these effects would be apparent in a clinical trial. METHODS: In this single-centre, randomised, double-blind, placebo-controll...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Lancet
Главные авторы: Athauda, Dilan, Maclagan, Kate, Skene, Simon S, Bajwa-Joseph, Martha, Letchford, Dawn, Chowdhury, Kashfia, Hibbert, Steve, Budnik, Natalia, Zampedri, Luca, Dickson, John, Li, Yazhou, Aviles-Olmos, Iciar, Warner, Thomas T, Limousin, Patricia, Lees, Andrew J, Greig, Nigel H, Tebbs, Susan, Foltynie, Thomas
Формат: Artigo
Язык:Inglês
Опубликовано: 2017
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5831666/
https://ncbi.nlm.nih.gov/pubmed/28781108
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(17)31585-4
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы